All In Biotech

NDA 214965 · Harrow Eye

Verkazia

Cyclosporine · Ophthalmic · Calcineurin Inhibitor Immunosuppressant

Orphan

Last checked: Nov 19, 2026Latest source record: Jun 23, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Jun 23, 2021

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,166

250 Phase 3, 65 recruiting

FAERS reports

57,120

51,865 serious, 10,991 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 4, 2026.

Verkazia ophthalmic emulsion is indicated for the treatment of vernal keratoconjunctivitis (VKC) in children and adults. Verkazia ophthalmic emulsion is a calcineurin inhibitor immunosuppressant indicated for the treatment of vernal keratoconjunctivitis in children and adults ( 1 )

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 23, 2021 Original approval · Type 5 - New Formulation or New Manufacturer OrphanLetterLabelReview
1 products under this application
  • VERKAZIA · CYCLOSPORINE 0.1% · EMULSION, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cyclosporine" as an intervention, any sponsor and status, largest first.

All 1,166 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use7,916
  • drug ineffective7,861
  • product use in unapproved indication3,634
  • pyrexia2,800
  • diarrhoea2,236
  • condition aggravated2,135
  • nausea2,044
  • pneumonia1,997
  • cytomegalovirus infection1,948
  • hypertension1,724
  • fatigue1,721
  • sepsis1,685

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004881
2005900
20061,029
2007984
20081,675
20091,917
20101,635
20112,284
20121,609
2013733
2014794
2015763
2016955
20171,234
20181,751
20192,425
20203,567
20213,629
20225,338
20235,473
20246,908
20256,091
20264,539

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Verkazia (Cyclosporine)

2024 spending

$260K

Beneficiaries

65

129 claims

Per beneficiary

$4,004

$14.56 per unit

View as table
YearSpending
2020$0
2021$0
2022$114,397
2023$283,074
2024$260,259

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,031 on PubMed

Sponsor: Harrow Eye

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.